Within-individual reproducibility of a dual sample oral cholate challenge test (DuO) and simplified versions of the HepQuant SHUNT test.
Journal
Clinical and translational science
ISSN: 1752-8062
Titre abrégé: Clin Transl Sci
Pays: United States
ID NLM: 101474067
Informations de publication
Date de publication:
Apr 2024
Apr 2024
Historique:
revised:
26
02
2024
received:
10
10
2023
accepted:
18
03
2024
medline:
1
4
2024
pubmed:
1
4
2024
entrez:
1
4
2024
Statut:
ppublish
Résumé
Current noninvasive liver tests measure fibrosis, inflammation, or steatosis and do not measure function. The HepQuant platform of noninvasive tests uniquely assesses both liver function and physiology through the hepatic uptake of stable isotopes of cholate. However, the prototypical HepQuant SHUNT test (SHUNT V1.0) is cumbersome to administer, requiring intravenous and oral administration of cholate and six peripheral venous blood samples over 90 min. To alleviate the burden of test administration, we explored whether an oral only (DuO) version, and other simplified versions, of the test could provide reproducible measurements of liver function. DuO requires only oral dosing and two blood samples over 60 min. The simplified SHUNT test versions were SHUNT V1.1 (oral and IV dosing but four blood samples) and SHUNT V2.0 (oral and IV dosing but only two blood samples over 60 min). In this paper, we describe the reproducibility of DuO and the simplified SHUNT tests relative to that of SHUNT V1.0; equivalency is described in a separate paper. Data from two studies comprising 236 SHUNT tests in 94 subjects were analyzed retrospectively by each method. All simplified methods were highly reproducible across test parameters with intraclass correlation coefficients >0.93 for test parameters Disease Severity Index (DSI) and Hepatic Reserve. DuO and SHUNT V2.0 improved reproducibility in measuring portal-systemic shunting (SHUNT%). These simplified tests, particularly DuO and SHUNT V2.0, are easier to administer and less invasive, thus, having the potential to be more widely accepted by care providers administering the test and by patients receiving the test.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13786Informations de copyright
© 2024 HepQuant LLC. Clinical and Translational Science published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics.
Références
American Liver Foundation. How many people have liver disease? https://liverfoundation.org/about‐your‐liver/facts‐about‐liver‐disease/how‐many‐people‐have‐liver‐disease
Idilman IS, Aniktar H, Idilman R, et al. Hepatic steatosis: quantification by proton density fat fraction with MR imaging versus liver biopsy. Radiology. 2013;267:767‐775.
Permutt Z, le TA, Peterson MR, et al. Correlation between liver histology and novel magnetic resonance imaging in adult patients with non‐alcoholic fatty liver disease – MRI accurately quantifies hepatic steatosis in NAFLD. Aliment Pharmacol Ther. 2012;36:22‐29.
Younossi ZM, Noureddin M, Bernstein D, et al. Role of noninvasive tests in clinical gastroenterology practices to identify patients with nonalcoholic Steatohepatitis at high risk of adverse outcomes: expert panel recommendations. Am J Gastroenterol. 2021;116:254‐262.
Metra BM, Guglielmo FF, Halegoua‐DeMarzio DL, Civan JM, Mitchell DG. Beyond the liver function tests: a Radiologist's guide to the liver blood tests. Radiographics. 2021;42:125‐142.
Davison BA, Harrison SA, Cotter G, et al. Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials. J Hepatol. 2020;73:1322‐1332.
Patel K, Sebastiani G. Limitations of non‐invasive tests for assessment of liver fibrosis. JHEP Rep. 2020;2:100067.
McRae MP, Helmke SM, Burton JR Jr, Everson GT. Compartmental model describing the physiological basis for the HepQuant SHUNT test. Transl Res. 2023;252:53‐63.
Burton JR, Helmke S, Lauriski S, Kittelson J, Everson GT. The within‐individual reproducibility of the disease severity index from the HepQuant SHUNT test of liver function and physiology. Transl Res. 2021;233:5‐15.
Everson GT, Helmke SM. Defining disease severity and measuring progression in primary sclerosing cholangitis (PSC): a comparison of the disease severity index (DSI) from the HepQuant SHUNT test with serum alkaline phosphatase (alk phos). Hepatology. 2018;68:1087A.
Everson GT, Martucci MA, Shiffman ML, et al. Portal‐systemic shunting in patients with fibrosis or cirrhosis due to chronic hepatitis C: the minimal model for measuring cholate clearances and shunt. Aliment Pharmacol Ther. 2007;26:401‐410.
Lemmens HJ, Bernstein DP, Brodsky JB. Estimating blood volume in obese and morbidly obese patients. Obes Surg. 2006;16:773‐776.
Everson GT, Shiffman ML, Morgan TR, et al. The spectrum of hepatic functional impairment in compensated chronic hepatitis C: results from the hepatitis C anti‐viral long‐term treatment against cirrhosis trial. Aliment Pharmacol Ther. 2008;27:798‐809.
Helmke SM, DeSanto J, Herman A, Lauriski S, Everson GT. A disease severity index based on dual cholate clearances and shunt outperforms biopsy at predicting clinical outcomes in chronic hepatitis C. Gastroenterology. 2013;144:S‐951‐S‐952.
Helmke S, Kulig C, Lauriski S, Herman A, Dudekula A, Everson G. Significant alteration of the portal circulation in over half of the chronic HCV patients with Ishak fibrosis stage F0‐F2. Hepatology. 2011;54:1328A‐1329A.
Koo TK, Li MY. A guideline of selecting and reporting Intraclass correlation coefficients for reliability research. J Chiropr Med. 2016;15:155‐163.
McGraw KO, Wong SP. Forming inferences about some intraclass correlation coefficients. Psychol Methods. 1996;1:30‐46.
Matheson GJ. We need to talk about reliability: making better use of test‐retest studies for study design and interpretation. PeerJ. 2019;7:e6918.
Weir JP. Quantifying test‐retest reliability using the intraclass correlation coefficient and the SEM. J Strength Cond Res. 2005;19:231‐240.
Baumgartner R, Joshi A, Feng D, Zanderigo F, Ogden RT. Statistical evaluation of test‐retest studies in PET brain imaging. EJNMMI Res. 2018;8:13.
Fallahzadeh MA, Hansen DJ, Trotter JF, et al. Predicting clinical decompensation in patients with cirrhosis using the Hepquant‐SHUNT test. Aliment Pharmacol Ther. 2021;53:928‐938.
Helmke SM, DeSanto J, Lauriski S, Wieland AC, Everson GT. Portal‐systemic shunt fraction measured by the HepQuant‐SHUNT test correlates with the hepatic venous pressure gradient (HVPG). Hepatology. 2017;66:348A.
Etzion O, Ali R, Zhang GY, et al. Liver functional assessment by dual cholate testing is strongly correlated with direct portal pressure and Ishak fibrosis stage. Hepatology. 2017;66:1036A‐1037A.
Hoteit M, Hsu CCS, Levine MH, et al. Deterioration of hepatic function after locoregional therapy (LRT) for hepatocellular carcinoma (HCC) measured by hepatic cholate clearance: a pilot study. J Clin Oncol. 2018;36:468.
Everson GT, Hoefs JC, Niemann CU, et al. Functional elements associated with hepatic regeneration in living donors after right hepatic lobectomy. Liver Transpl. 2013;19:292‐304.
Everson GT, Shiffman ML, Hoefs JC, et al. Quantitative tests of liver function measure hepatic improvement after sustained virological response: results from the HALT‐C trial. Aliment Pharmacol Ther. 2009;29:589‐601.
Everson GT, Helmke SM. Functional improvement measured by a reduction in HepQuant's disease severity index (DSI) after sustained viral response (SVR) in advanced hepatitis C is related to severity of hepatic impairment as determined by baseline DSI. Hepatology. 2019;70:334A.
Alkhouri N, Everson G, Helmke S, Chen J. Effect of obeticholic acid on liver function in patients with fibrosis due to NASH. J Hepatol. 2019;70:e149.
ClinicalTrials.gov. The SHUNT‐V Study for Varices. Accessed June 12, 2022 https://clinicaltrials.gov/ct2/show/NCT03583996
Shiffman ML, Leise MD, Reddy KR, et al. The HepQuant SHUNT test predicts the likelihood of finding esophageal varices and particularly large varices at endoscopy. Hepatology. 2021;74:1264A‐1265A.
Shiffman ML, Helmke SM, Everson GT. The HepQuant SHUNT disease severity index (HepQuant DSI) can aid the decision to avoid endoscopic screening or surveillance for varices needing treatment [abstract]. Gastroenterology. 2022;162:S‐1178.
McRae MP, Kittelson J, Helmke SM, Everson GT. Advances in noninvasive measurement of liver function and physiology: the HepQuant DuO test. Basic Clin Pharmacol Toxicol. 2024;134:385‐395.